2. Immunology/Inflammation
  3. Interleukin Related
  4. Simlukafusp alfa

Simlukafusp alfa  (Synonyms: FAP-IL2v)

Cat. No.: HY-P99902 Purity: 99.90%
COA

Molarity Calculator

Simlukafusp alfa (FAP-IL2v) is an immunocytokine comprising an antibody against fibroblast activation protein α (FAPα) and an IL-2 variant that only binds IL-2Rβγ. Isotype: human IgG1.

For research use only. We do not sell to patients.

Simlukafusp alfa Chemical Structure

Simlukafusp alfa Chemical Structure

CAS No. : 1776942-10-9

Size Price Stock Quantity
500 μg USD 1125 In-stock
1 mg USD 1800 In-stock
5 mg USD 4600 In-stock
10 mg   Get quote  
50 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Simlukafusp alfa Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Simlukafusp alfa (FAP-IL2v) is an immunocytokine comprising an antibody against fibroblast activation protein α (FAPα) and an IL-2 variant that only binds IL-2Rβγ. Isotype: human IgG1[1].

In Vitro

Simlukafusp alfa (FAP-IL2v) shows binding affinity constants of 43±9 pM, 80±20 pM, 660±80 pM, 0.3 nM, 0.23 nM and 0.5 nM with huIL-2Rβγ, cyIL-2Rβγ, muIL-2Rβγ, huFAP, cyFAP and muFAP, respectively[1].
Simlukafusp alfa (0-100 nM; 5 days) activates CD4+/CD8+ T cells and NK cells in vitro, but not preferentially Tregs[1].
Simlukafusp alfa (0-100 nM) enhances Cetuximab (HY-P9905)-mediated antibody-dependent cellular cytotoxicity (ADCC) and Cibisatamab (HY-P99011)-mediated T-cell-dependent cellular cytotoxicity (TDCC) in vitro[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Simlukafusp alfa Related Antibodies

Cell Proliferation Assay[1]

Cell Line: NK cells, CD4+ and CD8+ T cells
Concentration: 0-100 nM
Incubation Time: 5 days
Result: Induced a dose-dependent proliferation of resting NK cells and resting and activated CD4+ and CD8+ T cells within peripheral blood mononuclear cells (PBMCs).
In Vivo

Simlukafusp alfa (FAP-IL2v) (1 mg/kg; i.v.; weekly for 4 weeks) is efficacious in combination with therapeutic antibodies in murine models of human cancer[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: huCD16-transgenic SCID mice, lung orthotopic xenograft A549 model[1]
Dosage: 1 mg/kg in combination with 25 mg/kg Cetuximab (HY-P9905) as single agents
Administration: IV, weekly starting at Day 14 for 4 weeks
Result: Achieved greater tumor control than either agent given as monotherapy. Reduced tumor volume and tumor growth.
Animal Model: CD-1 mice[1]
Dosage: 1, 2 or 4 mg/kg
Administration: IV (Pharmacokinetic Analysis)
Result: Pharmacokinetic parameters after first dose of human FAP-IL2v (huFAP-IL2v) in CD-1 mice
CD-1 mice (n=10 per group) were given 1, 2, and 4 mg/kg huFAP-IL2v by IV administration once weekly. Multiple IV doses at 1 and 2 mg/kg were administered QW for up to a maximum of three doses, at which point toxicity was observed. Only a single dose was administered to the 4-mg/kg IV treatment group because of toxicity in these treatment groups. Blood was sampled at 0.5, 6, 24, 48, 72, and 168 h.
huFAP-IL2v dose (mg/kg) Cmax (μg/mL) AUC0-168h (μg•h/mL per mg/kg) CL (mL/d/kg)
1 19.0 557 40.0
2 36.3 479 46.8
4 78.7 541 38.7

AUC0-168h, area under the concentration-time curve from 0 to 168 hours; Cmax, maximum serum concentration observed; CL, total clearance; FAP-IL2v, fibroblast activation protein-α -targeted interleukin 2 variant (IL2v) immunocytokine; hu, humanized; IV, intravenous.
Clinical Trial
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Simlukafusp alfa]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation

Purity: 99.90%

COA (231 KB)

Handling Instructions (2659 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Simlukafusp alfa Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Simlukafusp alfa1776942-10-9FAP-IL2vInterleukin RelatedILFAPαfibroblast activation protein αIL-2RβγCetuximabCD4+CD8+NK cellInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Simlukafusp alfa
Cat. No.:
HY-P99902
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.